Medtech Business Models: All Razor And No Blades – Is “Big Iron” Back In Vogue?

The conventional wisdom in the medtech industry is to pursue the “razor-razor blade” business model, as each placement of capital equipment generates a lucrative annuity of recurring revenues from disposables. The corollary to this conventional wisdom is that so-called “big iron” is to be avoided as, in sharp contrast, it suffers from greater early cash requirements and longer sales cycles that create difficulties forecasting quarterly revenues, and provides no annuities. But that view is no longer the only one that counts, Health Advances CEO Mark Speers argues.

IV1901_Big-Iron_1268052778_1200.jpg
Big iron companies are challenging conventional business models • Source: Shutterstock

The razor-razor blade business model is pervasive in the medtech industry. As the conventional wisdom, it has a compelling logic. Each equipment placement leads to a lengthy revenue annuity. For example, over their seven-year lifetimes, the average volumetric infusion pump will consume over 1,500 proprietary IV set cassettes and the average breast biopsy device will consume about 3,500 needles.

For most razor-razor blade companies, disposable revenues dwarf capital revenues. For example, desktop chemistry analyzer company Abaxis Inc.’s revenue...

More from Market Intelligence

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.